

Anurag Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9434161/publications.pdf>

Version: 2024-02-01

19
papers

4,662
citations

686830

13
h-index

940134

16
g-index

19
all docs

19
docs citations

19
times ranked

9339
citing authors

#	ARTICLE	IF	CITATIONS
1	EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. <i>Oncogene</i> , 2010, 29, 4741-4751.	2.6	2,263
2	A Gene Expression Signature Associated with "K-Ras Addiction" Reveals Regulators of EMT and Tumor Cell Survival. <i>Cancer Cell</i> , 2009, 15, 489-500.	7.7	735
3	Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. <i>Cancer Research</i> , 2008, 68, 4853-4861.	0.4	474
4	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. <i>Cancer Cell</i> , 2013, 23, 121-128.	7.7	343
5	TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers. <i>Cell</i> , 2012, 148, 639-650.	13.5	245
6	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. <i>Journal of Clinical Investigation</i> , 2011, 121, 4311-4321.	3.9	177
7	Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. <i>Oncogene</i> , 2004, 23, 9369-9380.	2.6	157
8	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. <i>Cancer Research</i> , 2014, 74, 2825-2834.	0.4	61
9	Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. <i>Journal of Lipid Research</i> , 2003, 44, 1963-1975.	2.0	54
10	Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2008, 14, 6867-6876.	3.2	51
11	Oncogenic K-ras "addiction" and synthetic lethality. <i>Cell Cycle</i> , 2009, 8, 2676-2678.	1.3	34
12	Genetic and Pharmacologic Dissection of Ras Effector Utilization in Oncogenesis. <i>Methods in Enzymology</i> , 2006, 407, 195-217.	0.4	21
13	Regulation of autophagy, NF- κ B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. <i>Science Signaling</i> , 2017, 10, .	1.6	21
14	Transformation by a nucleotide-activated P2Y receptor is mediated by activation of G α_i , G α_q and Rho-dependent signaling pathways. <i>Journal of Molecular Signaling</i> , 2010, 5, 11.	0.5	9
15	MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. <i>Molecular Cancer Research</i> , 2016, 14, 1204-1216.	1.5	9
16	STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. <i>Oncotarget</i> , 2017, 8, 78556-78572.	0.8	8
17	Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. , 2008, , 103-126.		0
18	Knockdown and Inhibition of SYK Tyrosine Kinase Decreases mTORC1 Activity and Enhances Lysosomal Biogenesis and Autolysosomal Maturation in Pancreatic Cancer Cell Lines. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Knockdown and Inhibition of Spleen Tyrosine Kinase Decreases mTORC1 Activity and Enhances Lysosomal Biogenesis and Autolysosomal Maturation in Pancreatic Cancer Cell Lines. FASEB Journal, 2022, 36, .	0.2	0